Valuation: Alvotech

Market Cap 1.34B 1.16B 1.08B 997M 1.88B 128B 1.9B 12.73B 5B 63.85B 5.04B 4.93B 211B P/E 2026 *
14.2x
P/E 2027 * 8.2x
Enterprise Value 2.43B 2.1B 1.96B 1.8B 3.4B 231B 3.44B 23.01B 9.03B 115B 9.11B 8.91B 382B EV / Sales 2026 *
3.7x
EV / Sales 2027 * 3.04x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day-2.08%
Current month-59.91%
Current year-59.91%
5 years 3.67
Extreme 3.67
10.44
10 years 3.67
Extreme 3.67
11.62
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
21/9/20 OthersCompany 218,750 3.8889%
16/9/20 OtherCompany 0 0%
16/9/20 OtherCompany 6,468,750 115.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-2.08%+6.52% - - 1.34B
+1.19%-0.42%+4.11%+15.83% 48.57B
+1.98%+9.05%+413.94%+532.17% 41.95B
+3.44%-4.65%+28.34%+8.81% 38.85B
+1.40%+0.10%+6.61%+61.93% 37.24B
+2.42%+5.72%+12.38%+44.79% 30.67B
-0.16%-3.11% - - 16.1B
+2.20%+0.48%+34.71%+127.15% 16.41B
+0.57%+2.16%+8.48%+19.35% 13.97B
+4.25%-8.23%-1.49%-35.46% 12.62B
Average +1.52%-0.78%+63.38%+96.82% 28.48B
Weighted average by Cap. +1.91%-0.12%+83.07%+120.79%

Financials

2026 *2027 *
Net sales 656M 568M 530M 487M 920M 62.41B 930M 6.23B 2.44B 31.22B 2.46B 2.41B 103B 793M 686M 640M 588M 1.11B 75.36B 1.12B 7.52B 2.95B 37.7B 2.98B 2.91B 125B
Net income 91.8M 79.5M 74.11M 68.16M 129M 8.73B 130M 871M 342M 4.37B 345M 337M 14.46B 151M 131M 122M 112M 212M 14.39B 215M 1.44B 564M 7.2B 569M 556M 23.85B
Net Debt 1.08B 938M 875M 805M 1.52B 103B 1.54B 10.28B 4.03B 51.55B 4.07B 3.98B 171B 1.07B 923M 860M 791M 1.49B 101B 1.51B 10.11B 3.97B 50.68B 4B 3.91B 168B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
05/08/26 USD 3.760 -2.08% 741,941
04/08/26 USD 3.840 +1.32% 575,289
03/08/26 USD 3.790 -8.01% 1,026,989
31/07/26 USD 4.120 +15.41% 1,721,179
30/07/26 USD 3.570 +1.13% 989,695
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.760USD
Average target price
5.750USD
Spread / Average Target
+52.93%

Quarterly revenue - Rate of surprise